Regulus Therapeutics INC 8-K filings

Regulus Therapeutics Inc. has been acquired by Novartis AG's indirect wholly-owned subsidiary, Redwood Merger Sub Inc., for $7.00 per share in cash plus a contingent value right, following a successful tender offer.

Regulus Therapeutics announces acquisition by Novartis for $7.00 per share in cash, with a potential additional $7.00 per share via a contingent value right, alongside positive Phase 1b data for farabursen in ADPKD.

Novartis AG will acquire Regulus Therapeutics for $7.00 per share in cash, plus a contingent value right (CVR) of up to $7.00 per share, potentially valuing the company at approximately $1.7 billion.

Regulus Therapeutics reports positive topline results from the fourth cohort of its Phase 1b study of farabursen (RGLS8429) for autosomal dominant polycystic kidney disease (ADPKD), showing a halting of kidney volume growth.

Regulus Therapeutics reported positive interim results from a Phase 1b trial of farabursen for ADPKD and alignment with the FDA on a Phase 3 trial design, along with its year-end 2024 financial results.

Regulus Therapeutics extends its lease agreement for its San Diego facility, ensuring continued operations at its current location until April 2028.

Regulus Therapeutics reported its third quarter 2024 financial results, highlighted by the completion of enrollment in a Phase 1b clinical trial for its ADPKD treatment and a cash runway into the first half of 2026.

Regulus Therapeutics has obtained an exclusive, worldwide license from The University of Texas Southwestern Medical Center for technology related to treating autosomal dominant polycystic kidney disease.

Regulus Therapeutics reported positive topline data from their Phase 1b study of RGLS8429 for ADPKD and announced their Q2 2024 financial results, ending the quarter with $95.9 million in cash.

Regulus Therapeutics reported positive topline results from the third cohort of its Phase 1b study of RGLS8429 for autosomal dominant polycystic kidney disease (ADPKD), showing a dose response and reduction in kidney volume.

Regulus Therapeutics' stockholders approved an amendment to the 2019 Equity Incentive Plan, increasing the number of shares available for issuance, and elected ten directors at the 2024 Annual Meeting.

Regulus Therapeutics reported its first quarter 2024 financial results, highlighted by the initiation of the final cohort in its Phase 1b trial for RGLS8429 and a strong cash position.

Regulus Therapeutics reported positive topline data from its Phase 1b trial for RGLS8429 in ADPKD and completed a $100 million private placement.

Regulus Therapeutics has successfully completed a $100 million private placement to advance its microRNA-targeting drug pipeline.